RecruitingNCT04286360

Hematological Anomalies in Children With Rasopathy


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

300 participants

Start Date

Nov 11, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative disorders. These anomalies may spontaneously disappear or persist, sometimes leading to juvenile myelomonocytic leukemia. Guidelines for initial screening and subsequent hematological follow-up have recently been published in France: peripheral blood analysis should be performed in all newly diagnosed patients and followed by biannual peripheral blood analysis in infants until the age of 2 years. In order to describe the characteristics of these abnormalities in terms of their incidence, age of occurrence, evolution and relation to genotype, we are conducting a longitudinal prospective study whose aim is to analyze peripheral blood cell counts and smears at diagnosis and one year later. In patients \<3 years of age recruited at certain centers, biobanking of mononuclear cells will be performed. These data could yield a new insight into hematological anomalies in patients with RASopathies and thereby help physicians to determine the appropriate rhythm for hematological follow-up according to genotype.


Eligibility

Max Age: 15 Years

Inclusion Criteria5

  • Age < 16 years
  • Patient newly diagnosed with genetically confirmed rasopathy : Noonan syndrome, type 1 neurofibromatosis, Noonan syndrome with multiple lentigines, CBL syndrome, Costello syndrome, cardiofaciocutaneous syndrome or Legius syndrome i.e. with a germline mutation of one of these genes: PTPN11, SOS1, NRAS, RAF1, BRAF, SHOC2, MEK1, MEK2, CBL, NF1, SPRED1, KRAS, HRAS, NF1, SHOC2, LZTR1, SOS2, RIT1, RASA2, RRAS, PPP1CB, or a new gene of interest published during the recruitment period
  • No history of hematological malignancy
  • Written informed consent obtained from the parents
  • Health insurance

Exclusion Criteria1

  • History of malignant hematological pathology

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(14)

CHU Angers

Angers, France

CHU Caen

Caen, France

CHU Lille

Lille, France

CHU Lyon

Lyon, France

CHU Marseille - Hôpital de la Timone

Marseille, France

CHU Montpellier

Montpellier, France

CHU Nantes

Nantes, France

Hôpital Necker APHP

Paris, France

Hôpital Robert Debré APHP

Paris, France

Hôpital Robert Debré APHP

Paris, France

Hôpital Trousseau APHP

Paris, France

CHU Rennes

Rennes, France

CHU Strasbourg

Strasbourg, France

CHU Toulouse

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04286360


Related Trials